OpenAI acquires drug development platform Orchestra Bio
OpenAI announced it has acquired Orchestra Bio, a platform that helps pharmaceutical companies coordinate development work. Orchestra's team and technology will join Rosalind, OpenAI's life sciences initiative. The company aims to cut operational delays in drug development using AI agents.
